This inventor holds 2 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Axceso Biopharma Co., Ltd., Axceso Biopharma Co., Ltd.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Young Jun Park: Innovator in Parkinson's Disease Treatment
Introduction
Young Jun Park is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neurodegenerative diseases such as Parkinson's disease. His innovative work focuses on developing compositions that can potentially improve the quality of life for those affected by this condition.
Latest Patents
Young Jun Park holds a patent for a composition comprising O-cyclic phytosphingosine-1-phosphate aimed at preventing or treating Parkinson's disease. This pharmaceutical or health food composition is designed to prevent the death of SH-SY5Y nerve cells, which are crucial dopaminergic nerve cells. The composition also enhances the expression of tyrosine hydroxylase, an enzyme essential for dopamine formation. As a result, this innovative composition can be effectively utilized in the prevention or treatment of Parkinson's disease. He has 1 patent to his name.
Career Highlights
Young Jun Park is associated with Axceso Biopharma Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to finding effective solutions for complex health issues.
Collaborations
He collaborates with esteemed colleagues, including Won Kyo Han and Myeong Jun Choi, who contribute to his research endeavors and help drive innovation in the field.
Conclusion
Young Jun Park is a dedicated inventor whose work in developing treatments for Parkinson's disease showcases his commitment to improving health outcomes. His innovative compositions hold promise for the future of neurodegenerative disease treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile